Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17164754 | 0.81 | MKNK2 (0.41) | EGFRALDH1A1KDM4ECHEK1MAPT | |
| SCHEMBL30990399 | 0.77 | MKNK2 (0.44) | EGFRMKNK2 | |
| SCHEMBL20980517 | 0.66 | ADORA2A (0.45) | EGFRALDH1A1KDM4ECHEK1MAPT | |
| SCHEMBL8581523 | 0.66 | ALDH1A1 (0.42) | ALDH1A1KDM4ECHEK1MAPTLIMK1 | |
| SCHEMBL30718003 | 0.66 | MKNK2 (0.34) | MKNK2 | |
| SCHEMBL9752552 | 0.63 | ALDH1A1 (0.37) | ALDH1A1KDM4ECHEK1MAPTLIMK1 | |
| SCHEMBL16771011 | 0.63 | CCNB2 (0.51) | EGFRALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL64923 | 0.63 | ALDH1A1 (0.42) | ALDH1A1KDM4ECHEK1MAPTLIMK1 | |
| SCHEMBL30307422 | 0.63 | ALDH1A1 (0.42) | ALDH1A1KDM4ECHEK1MAPTLIMK1 | |
| SCHEMBL3761998 | 0.63 | KDM4E (0.62) | EGFRALDH1A1KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848634-B | Pyrimido [5,4-b ] pyridine compounds, optical isomers, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-07-07 | — | — | CN | disclosed |
| CN-114478548-A | Application of Bruton's tyrosine kinase inhibitor | 上海润石医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022083745-A1 | USE OF BRUTON'S TYROSINE KINASE INHIBITOR | 中国科学院上海药物研究所 | 2022-04-28 | — | — | WO | disclosed |
| CN-109983016-B | Pyrimido [5,4-b ] indolizine or pyrimido [5,4-b ] pyridine compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-02-01 | — | — | CN | disclosed |
| CN-109983016-B | Pyrimido [5,4-b ] indolizine or pyrimido [5,4-b ] pyridine compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2022-02-01 | — | — | CN | disclosed |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-3546460-B1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-07-08 | — | — | EP | disclosed |
| EP-3546460-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3546460-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-10-02 | — | — | EP | disclosed |
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-26 | — | — | US | disclosed |
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-26 | — | — | US | disclosed |
| WO-2018095398-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292183-A1 | PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, PREPARATION METHOD AND USE THEREOF | BTK, SYK, CDK8 | EGFR 1581/4885ALDH1A1 4769/4885KDM4E 1219/4885 |
| US-10829491-B2 | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | BTK, SYK, CDK8 | EGFR 1581/4885ALDH1A1 4769/4885KDM4E 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.